Additional Study Information: The purpose of this protocol is to describe the acquisition and analysis of tumor tissue samples, with the goal of identifying master regulator genes that may be targeted by existing FDA-approved drugs or late-stage experimental compounds, either individually or in combination. Should we be able to predict such therapeutic targets, drug screening will be performed in vitro and in vivo to test the accuracy of our computational inferences. Subjects must be diagnosed with one of the following cancers: a) Gastrointestinal neuroendocrine tumors, b) Glioma, c) Gastric adenocarcinoma, d) Lung adenocarcinoma, e) Pancreatic adenocarcinoma, f) Soft tissue sarcoma, g) Metastatic breast cancer, h) Triple-negative breast cancer, i) Squamous cell carcinoma of the head and neck, j) Metastatic colorectal cancer, k) Atypical meningioma, l) Metastatic melanoma, m) Metastatic renal cell carcinoma, or n) Bladder cancer.